InterCure finalized a settlement with Israeli authorities for NIS 230 million (approximately US$77 million) in compensation for war-related indirect damages stemming from the October 7, 2023 attacks. This amount reduces the company's original claim of over NIS 300 million and follows prior advance payments of NIS 101 million. The settlement allows InterCure to accelerate the rehabilitation of its flagship Canndoc facility at Kibbutz Nir Oz, which was severely damaged in the conflict, aiming to restore full production capabilities. This financial resolution supports the company's strategy to expand into the German medical cannabis market and return to growth following a period of operational recovery. InterCure operates in the medical cannabis industry as Israel’s largest licensed producer.
